fashion -WSS

fashion

author：hotspot 2025-10-01 02:15:40 - browse：21778

Maze Therapeutics CEO Jason Coloma Courtesy

After seeing its last deal go bust in the face of regulatory scrutiny, Maze Therapeutics has found another suitor for its experimental Pompe disease treatment.

Bay Area-based Maze and Shionogi said Friday that the Japanese pharma company had licensed the drug, called MZE001, with an upfront payment of $150 million. The global deal includes additional, undisclosed payments if the oral medication, which is in clinical testing, meets certain regulatory and commercial goals.

Last year, Sanofi, the French pharma giant, was set to pay $150 million in cash and stock to Maze before the transaction fell apart.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： What’s missing from the debate over nursing home staff minimums

knowledge

WSS

The Biogen Aduhelm mess could happen again

Tesla recalling nearly 16,000 of its 2021

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Mass General totes up its waste in a move to tackle climate change

Problems with a popular proposal to regulate AI in health care

I learned firsthand about improving diversity in clinical trials

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

23andMe had bad news about my health. I wish a person had delivered it

Updated Covid vaccine has 54% effectiveness, new study suggests

In age of alternative facts, a scholarly course on calling out crap

Medicare Advantage plans can’t deny care with AI, CMS warns

Walensky prepares to leave CDC — and Congress — behind

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Activists slam private health insurers over coverage restrictions

Texas Medical Board asked to define abortion emergency exception

Activists slam private health insurers over coverage restrictions

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

leisure time

Why Novartis is going to walk from its acquisition of MorphoSys

Mass General totes up its waste in a move to tackle climate change

Why Novartis is going to walk from its acquisition of MorphoSys

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Adopting new red light myopia treatments may be short

Top private equity targets in 2023: cardiology, clinical trials, lasers

hotspot

explore

knowledge

focus